325 related articles for article (PubMed ID: 37110848)
1. Multiple Strategies to Develop Small Molecular KRAS Directly Bound Inhibitors.
Zhou X; Ji Y; Zhou J
Molecules; 2023 Apr; 28(8):. PubMed ID: 37110848
[TBL] [Abstract][Full Text] [Related]
2. Multiple medicinal chemistry strategies of targeting KRAS: State-of-the art and future directions.
Shang Y; Fu S; Hao Q; Ying H; Wang J; Shen T
Bioorg Chem; 2024 Mar; 144():107092. PubMed ID: 38271825
[TBL] [Abstract][Full Text] [Related]
3. Glimmers of hope for targeting oncogenic KRAS-G12D.
Tang D; Kang R
Cancer Gene Ther; 2023 Mar; 30(3):391-393. PubMed ID: 36414681
[TBL] [Abstract][Full Text] [Related]
4. Targeting KRAS in pancreatic cancer: Emerging therapeutic strategies.
Khan S; Budamagunta V; Zhou D
Adv Cancer Res; 2023; 159():145-184. PubMed ID: 37268395
[TBL] [Abstract][Full Text] [Related]
5. KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments.
Koga T; Suda K; Fujino T; Ohara S; Hamada A; Nishino M; Chiba M; Shimoji M; Takemoto T; Arita T; Gmachl M; Hofmann MH; Soh J; Mitsudomi T
J Thorac Oncol; 2021 Aug; 16(8):1321-1332. PubMed ID: 33971321
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the binding of MRTX1133 as an avenue for the discovery of potential KRAS
Issahaku AR; Mukelabai N; Agoni C; Rudrapal M; Aldosari SM; Almalki SG; Khan J
Sci Rep; 2022 Oct; 12(1):17796. PubMed ID: 36273239
[TBL] [Abstract][Full Text] [Related]
7.
Ceddia S; Landi L; Cappuzzo F
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012655
[No Abstract] [Full Text] [Related]
8. Drugging KRAS: current perspectives and state-of-art review.
Parikh K; Banna G; Liu SV; Friedlaender A; Desai A; Subbiah V; Addeo A
J Hematol Oncol; 2022 Oct; 15(1):152. PubMed ID: 36284306
[TBL] [Abstract][Full Text] [Related]
9. Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS
Wang X; Allen S; Blake JF; Bowcut V; Briere DM; Calinisan A; Dahlke JR; Fell JB; Fischer JP; Gunn RJ; Hallin J; Laguer J; Lawson JD; Medwid J; Newhouse B; Nguyen P; O'Leary JM; Olson P; Pajk S; Rahbaek L; Rodriguez M; Smith CR; Tang TP; Thomas NC; Vanderpool D; Vigers GP; Christensen JG; Marx MA
J Med Chem; 2022 Feb; 65(4):3123-3133. PubMed ID: 34889605
[TBL] [Abstract][Full Text] [Related]
10. Annual review of KRAS inhibitors in 2022.
Wang H; Chi L; Yu F; Dai H; Gao C; Si X; Wang Z; Liu L; Zheng J; Shan L; Liu H; Zhang Q
Eur J Med Chem; 2023 Mar; 249():115124. PubMed ID: 36680986
[TBL] [Abstract][Full Text] [Related]
11. Small-Molecule Inhibitors and Degraders Targeting KRAS-Driven Cancers.
Hyun S; Shin D
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830024
[TBL] [Abstract][Full Text] [Related]
12. KRAS G12D targeted therapies for pancreatic cancer: Has the fortress been conquered?
Bannoura SF; Khan HY; Azmi AS
Front Oncol; 2022; 12():1013902. PubMed ID: 36531078
[TBL] [Abstract][Full Text] [Related]
13.
Miyamoto-Sato E; Imanishi S; Huang L; Itakura S; Iwasaki Y; Ishizaka M
Molecules; 2023 Jul; 28(14):. PubMed ID: 37513471
[TBL] [Abstract][Full Text] [Related]
14. KRAS mutation: from undruggable to druggable in cancer.
Huang L; Guo Z; Wang F; Fu L
Signal Transduct Target Ther; 2021 Nov; 6(1):386. PubMed ID: 34776511
[TBL] [Abstract][Full Text] [Related]
15. KRAS-targeted therapy in the treatment of non-small cell lung cancer.
Yun J; Nakagawa R; Tham K
J Oncol Pharm Pract; 2023 Mar; 29(2):422-430. PubMed ID: 35938195
[TBL] [Abstract][Full Text] [Related]
16. Inhibition mechanism of MRTX1133 on KRAS
Liang F; Kang Z; Sun X; Chen J; Duan X; He H; Cheng J
J Comput Aided Mol Des; 2023 Mar; 37(3):157-166. PubMed ID: 36849761
[TBL] [Abstract][Full Text] [Related]
17. BCL-X
Khan S; Wiegand J; Zhang P; Hu W; Thummuri D; Budamagunta V; Hua N; Jin L; Allegra CJ; Kopetz SE; Zajac-Kaye M; Kaye FJ; Zheng G; Zhou D
J Hematol Oncol; 2022 Mar; 15(1):23. PubMed ID: 35260176
[TBL] [Abstract][Full Text] [Related]
18. KRAS: A Druggable Target in Colon Cancer Patients.
Negri F; Bottarelli L; de'Angelis GL; Gnetti L
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35456940
[TBL] [Abstract][Full Text] [Related]
19. KRAS Inhibitors- yes but what next? Direct targeting of KRAS- vaccines, adoptive T cell therapy and beyond.
Nagasaka M; Potugari B; Nguyen A; Sukari A; Azmi AS; Ou SI
Cancer Treat Rev; 2021 Dec; 101():102309. PubMed ID: 34715449
[TBL] [Abstract][Full Text] [Related]
20. KRAS-G12C covalent inhibitors: A game changer in the scene of cancer therapies.
Naim N; Moukheiber S; Daou S; Kourie HR
Crit Rev Oncol Hematol; 2021 Dec; 168():103524. PubMed ID: 34800654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]